ECSP15050386A - FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc - Google Patents

FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc

Info

Publication number
ECSP15050386A
ECSP15050386A ECIEPI201550386A ECPI201550386A ECSP15050386A EC SP15050386 A ECSP15050386 A EC SP15050386A EC IEPI201550386 A ECIEPI201550386 A EC IEPI201550386A EC PI201550386 A ECPI201550386 A EC PI201550386A EC SP15050386 A ECSP15050386 A EC SP15050386A
Authority
EC
Ecuador
Prior art keywords
tnfr
fusion polypeptides
alternative formulations
formulations
alternative
Prior art date
Application number
ECIEPI201550386A
Other languages
English (en)
Inventor
Raha Tamal
Bes Cédric
Bañado Carlos
Original Assignee
Mabxience S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15050386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mabxience S A filed Critical Mabxience S A
Publication of ECSP15050386A publication Critical patent/ECSP15050386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas estables acuosas adecuadas para el almacenamiento de polipéptidos que contienen TNFR: Fc.
ECIEPI201550386A 2013-05-02 2015-12-02 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc ECSP15050386A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166230 2013-05-02
EP13166228 2013-05-02
EP13180169 2013-08-13

Publications (1)

Publication Number Publication Date
ECSP15050386A true ECSP15050386A (es) 2015-12-31

Family

ID=50732113

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201550386A ECSP15050386A (es) 2013-05-02 2015-12-02 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc

Country Status (16)

Country Link
US (1) US20160106844A1 (es)
EP (1) EP2991668A1 (es)
JP (2) JP2016518386A (es)
KR (1) KR20160008575A (es)
CN (1) CN105873601A (es)
AU (1) AU2014261477A1 (es)
BR (1) BR112015027764A2 (es)
CA (1) CA2911068A1 (es)
EC (1) ECSP15050386A (es)
HK (1) HK1221163A1 (es)
MX (1) MX2015015051A (es)
RU (1) RU2663727C2 (es)
SG (1) SG11201508900UA (es)
TW (2) TW201534349A (es)
UY (2) UY35549A (es)
WO (1) WO2014177548A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN110495447A (zh) * 2019-09-10 2019-11-26 湖南思为康医药有限公司 一种免疫细胞玻璃化冻存保护液及冻存免疫细胞的方法
AU2022359021A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CN103930124B (zh) * 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
MX366622B (es) * 2012-10-26 2019-07-16 Lupin Atlantis Holdings Sa Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins

Also Published As

Publication number Publication date
AU2014261477A1 (en) 2015-11-19
EP2991668A1 (en) 2016-03-09
TW201540321A (zh) 2015-11-01
WO2014177548A1 (en) 2014-11-06
BR112015027764A2 (pt) 2017-08-29
UY35811A (es) 2015-05-29
SG11201508900UA (en) 2015-11-27
JP2018109064A (ja) 2018-07-12
HK1221163A1 (zh) 2017-05-26
RU2015151606A (ru) 2017-06-06
JP2016518386A (ja) 2016-06-23
TW201534349A (zh) 2015-09-16
KR20160008575A (ko) 2016-01-22
MX2015015051A (es) 2016-06-10
CN105873601A (zh) 2016-08-17
CA2911068A1 (en) 2014-11-06
RU2663727C2 (ru) 2018-08-08
UY35549A (es) 2014-11-28
US20160106844A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
ECSP15050386A (es) FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
SV2016005186A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
DOP2016000145A (es) Reguladores de nrf2
MX395458B (es) Metodos novedosos
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
DOP2013000307A (es) Antagonistas de trpv4
CL2017000270A1 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias.
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
MX2014001368A (es) Soluciones anti-inflamatorias estables para inyección.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
EA201501163A1 (ru) Модуляторы рецептора cxcr7
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo